Epimedin A
Based on 4 publication(s) in Google Scholar
Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.43%
- No. CAS: 110623-72-8
- Fòrmula: C39H50O20
- Peso molecular:838.80
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Natural Product Library
HY-L021
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Glycoside Compound Library
HY-L042
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Glycolysis Compound Library
HY-L058
-
Pyroptosis Compound Library
HY-L059
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Flavonoids Library
HY-L068
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Glucose Metabolism Compound Library
HY-L092
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Protease Inhibitor Library
HY-L147
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Cytokine Inhibitors Library
HY-L161
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Pattern Recognition Receptors Library
HY-L237
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Tonifying Traditional Chinese Medicine Monomer Compound Library
HY-L246
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Epimedin A
MoreVer todos los productos específicos de isoformas Caspase
More
Actividad biológica
|
NLRP3 |
HO-1 |
Caspase-1 |
Caspase-8 |
IL-1β |
IL-6 |
Epimedin A (0.1-0.4 μM; 5 days) inhibits RANKL/M-CSF-induced osteoclast differentiation and reduces the mRNA expression of osteoclast-related genes in RAW264.7 cells. The mechanism involves the inhibition of the TRAF6/PI3K/AKT/NF-κB pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7 cells treated RANKL and M-CSF
-
Concentration:0.1, 0.2 and 0.4 μM
-
Incubation Time:5 days
-
Result:Inhibited the mRNA levels of the osteoclast-related genes NFATc1, Ctsk, Oscar and Trap.
Epimedin A (5-20 mg/kg; oral administration; 11 days) exerts an anti-inflammatory effect in a mouse model of allergic contact dermatitis (CD)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Wistar rats (240±20 g, 10-12 weeks old) were ovariectomized to establish an osteoporosis model[1]
-
Dosage:5, 10 and 20 mg/kg
-
Administration:Oral administration; 90 days
-
Result:Increased bone density, relative bone volume, trabecular thickness and number, as well as reduced trabecular separation in the ovariectomized rats.
Dose-dependently normalized bone density and trabecular microarchitecture in the ovariectomized rats.
Inhibited the expression of TRAP and NFATc1 in the ovariectomized rats.
-
Animal Model:BALB/c mice aged 7 weeks old (20-25 g) treated DNFB to establish CD model[2]
-
Dosage:5, 10 and 20 mg/kg
-
Administration:Oral administration; 11 days
-
Result:Significantly and dose-dependently ameliorated DNFB-induced CD, as evidenced by repression of scratching behavior, dermatitis score, ear thickness and weight, and histopathological changes in ear tissues, as well as reduction of collagen fiber area percent.
Suppressed NF-κB/NLRP3 pathway, enhanced Nrf2/HO-1 pathway, reduced oxidative stress markers (MDA), increased antioxidant markers (GSH, SOD), inhibited pyroptosis-related molecules (NLRP3, ASC, caspase-1, 8, GSDMD, LDH), and decreased inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-4, IFN-γ) and IgE levels (t-IgE, s-IgE, s-IgE/t-IgE ratio).
Chemical Information
-
No. CAS 110623-72-8
-
Appearance Solid
-
Peso molecular 838.80
-
Fòrmula C39H50O20
-
Color Light yellow to yellow
-
SMILES
O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](OC2=CC(O)=C(C(C(O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O[C@@]4([H])[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C(C5=CC=C(OC)C=C5)O6)=O)C6=C2C/C=C(C)/C)[C@@H]1O
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]2021 Jan;11(1):143-155. PMID: 33532186 -
Food Chem
Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]2025 Dec 30:497:146992. PMID: 41285060 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 May 31:489:144992. PMID: 40466530 -
J Pharm Pharmacol
Icariside I reduces breast cancer proliferation, apoptosis, invasion, and metastasis probably through inhibiting IL-6/STAT3 signaling pathway. [Abstract]2024 May 3;76(5):499-513. PMID: 37971302
Solvente y solubilidad
DMSO : 250 mg/mL (298.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 6.25 mg/mL (7.45 mM); Clear solution
This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 6.25 mg/mL (7.45 mM); Clear solution
This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Li J, et al. Epimedin A inhibits the PI3K/AKT/NF-κB signalling axis and osteoclast differentiation by negatively regulating TRAF6 expression. Mol Med. 2024 Aug 16;30(1):125. [Content Brief]
[2]. Balaha MF, et al. Epimedin A ameliorates DNFB-induced allergic contact dermatitis in mice: Role of NF-κB/NLRP3-driven pyroptosis, Nrf2/HO-1 pathway, and inflammation modulation. Life Sci. 2022 Aug 1;302:120653. [Content Brief]
[3]. Zhang HF, et al. Simultaneous extraction of epimedin A, B, C and icariin from Herba Epimedii by ultrasonic technique. Ultrason Sonochem. 2008 Apr;15(4):376-85. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1922 mL | 5.9609 mL | 11.9218 mL | 29.8045 mL |
| 5 mM | 0.2384 mL | 1.1922 mL | 2.3844 mL | 5.9609 mL | |
| 10 mM | 0.1192 mL | 0.5961 mL | 1.1922 mL | 2.9804 mL | |
| 15 mM | 0.0795 mL | 0.3974 mL | 0.7948 mL | 1.9870 mL | |
| 20 mM | 0.0596 mL | 0.2980 mL | 0.5961 mL | 1.4902 mL | |
| 25 mM | 0.0477 mL | 0.2384 mL | 0.4769 mL | 1.1922 mL | |
| 30 mM | 0.0397 mL | 0.1987 mL | 0.3974 mL | 0.9935 mL | |
| 40 mM | 0.0298 mL | 0.1490 mL | 0.2980 mL | 0.7451 mL | |
| 50 mM | 0.0238 mL | 0.1192 mL | 0.2384 mL | 0.5961 mL | |
| 60 mM | 0.0199 mL | 0.0993 mL | 0.1987 mL | 0.4967 mL | |
| 80 mM | 0.0149 mL | 0.0745 mL | 0.1490 mL | 0.3726 mL | |
| 100 mM | 0.0119 mL | 0.0596 mL | 0.1192 mL | 0.2980 mL |
Powered by Bioz